CN109998102B - L-carnitine lotus leaf green tea capsule and preparation method thereof - Google Patents
L-carnitine lotus leaf green tea capsule and preparation method thereof Download PDFInfo
- Publication number
- CN109998102B CN109998102B CN201910278268.4A CN201910278268A CN109998102B CN 109998102 B CN109998102 B CN 109998102B CN 201910278268 A CN201910278268 A CN 201910278268A CN 109998102 B CN109998102 B CN 109998102B
- Authority
- CN
- China
- Prior art keywords
- parts
- carnitine
- green tea
- lotus
- lotus leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 63
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 63
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 63
- 239000002775 capsule Substances 0.000 title claims abstract description 45
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 35
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 18
- QDOXWKRWXJOMAK-UHFFFAOYSA-N dichromium trioxide Chemical compound O=[Cr]O[Cr]=O QDOXWKRWXJOMAK-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 235000009569 green tea Nutrition 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 10
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 27
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940094952 green tea extract Drugs 0.000 claims abstract description 17
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 17
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims abstract description 17
- 238000011049 filling Methods 0.000 claims abstract description 14
- 239000011812 mixed powder Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 206010012735 Diarrhoea Diseases 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 206010033557 Palpitations Diseases 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 208000002173 dizziness Diseases 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 9
- 239000000047 product Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 229960001518 levocarnitine Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses an L-carnitine lotus leaf green tea capsule which comprises the following raw materials in parts by weight: 270 parts of L-carnitine tartrate 250-one, 30-40 parts of lotus leaf extract, 40-50 parts of green tea extract, 70-80 parts of lotus seed powder and 3-6 parts of limonin. Tests prove that the incidence rate of adverse reactions such as L-carnitine insomnia, accelerated heartbeat, dizziness, palpitation, diarrhea and the like is reduced, and the weight-losing effect is better. And after the lotus seed powder is added, other auxiliary materials are not required to be added, and the total mixed powder has better powder property and meets the filling requirement of the capsule.
Description
Technical Field
The invention relates to an L-carnitine lotus leaf green tea capsule and a preparation method thereof.
Background
Along with social development, the living standard of people is gradually increased, the rhythm of life is also gradually increased, and at present, factors such as food eaten by people, the environment where people are located, lack of sports and the like cause that many people are in unhealthy or sub-healthy states, and the occurrence probability of obesity, hyperlipidemia and other problems is high.
L-carnitine (also called L-carnitine) is an amino acid class which promotes fat to be converted into energy, and red meat is a main source of the L-carnitine. L-carnitine is an amino acid-like substance naturally existing in human bodies and has the functions of transporting fat to mitochondria and accelerating the combustion and decomposition of the fat, so that consumers can lose weight. Different types of diets already contain 5-100 mg of l-carnitine, but generally only 50 mg per day can be ingested by people from the diet, and less by vegetarians. The main physiological function of the L-carnitine is to promote fat to be converted into energy, and the L-carnitine can reduce body fat and weight without reducing water and muscle, so that the L-carnitine is considered as a safer weight-reducing nutritional supplement.
For example, CN201710404140.9 discloses a lotus leaf L-carnitine solid beverage and a preparation method thereof. Weighing L-carnitine tartrate and folium Nelumbinis extract, respectively sieving with 100 mesh sieve, mixing, and packaging. The invention can promote fat to be converted into energy amino-like acid, has no toxic or side effect on human body, and has the effects of clearing away heart-fire, relieving summer-heat, removing blood stasis, stopping bleeding, dispelling wind and eliminating dampness. There are also many products containing l-carnitine on the market today, such as: the raw materials of the Newberle L-carnitine lotus leaf green tea capsule are L-carnitine tartrate, lotus leaf extract and green tea extract, and the lotus leaf extract and the green tea extract are added to increase the weight-losing effect. However, the L-carnitine has side effects of insomnia, accelerated heartbeat, dizziness, palpitation, diarrhea, malnutrition and the like, so that the application of the L-carnitine is limited.
Disclosure of Invention
The invention aims to solve the technical problem of providing a weight-losing L-carnitine product with good effect and small side effect.
In order to solve the technical problems, the invention discloses an L-carnitine lotus leaf green tea capsule which comprises the following raw materials in parts by weight: 270 parts of L-carnitine tartrate 250-one, 30-40 parts of lotus leaf extract, 40-50 parts of green tea extract, 70-80 parts of lotus seed powder and 3-6 parts of limonin.
Preferably comprises the following raw materials in parts by weight: 260 parts of L-carnitine tartrate, 35 parts of lotus leaf extract, 45 parts of green tea extract, 76 parts of lotus seed powder and 4 parts of limonin.
The L-carnitine lotus leaf green tea capsule disclosed by the invention is added with lotus seed powder and limonin in a proper proportion on the basis of L-carnitine tartrate, lotus leaf extract and green tea extract which have the weight-losing effect, and the lotus seed powder has the effects of tonifying spleen, stopping diarrhea, tonifying kidney, arresting seminal emission, nourishing heart and soothing nerves; the limonin has health care effects of improving sleep, resisting anxiety, calming and the like, and through the matching of various components, the incidence rate of adverse reactions such as L-carnitine insomnia, accelerated heartbeat, dizziness, palpitation, diarrhea and the like is reduced, and the limonin has a better weight-losing effect. And after the lotus seed powder is added, other auxiliary materials are not required to be added, and the total mixed powder has better powder property and meets the filling requirement of the capsule.
The lotus seed powder can be prepared by the following steps: a) removing impurities from semen Nelumbinis, and drying; b) primary crushing; c) and (4) micronizing. The lotus seed powder prepared by the optimized method has fine and smooth powder, uniform particle size and good effect.
The L-carnitine lotus leaf green tea capsule disclosed by the invention can be prepared by the following steps: a) sieving the raw materials for later use; b) weighing L-carnitine tartrate, lotus leaf extract, green tea extract and lotus seed powder according to the formula proportion, uniformly mixing, adding limonin with the formula amount, and mixing to obtain total mixed powder; c) and filling the total mixed powder into capsules by using a capsule filling machine to obtain the capsule.
Detailed Description
The above-mentioned aspects of the present invention will be further described in detail with reference to the following specific examples. It should not be understood that the scope of the above-described subject matter of the present invention is limited to the following examples. Various substitutions and alterations according to the general knowledge and conventional practice in the art are intended to be included within the scope of the present invention without departing from the technical spirit of the present invention as described above.
Example 1
Prescription:
| composition of matter | Dosage (kg) |
| L-carnitine tartrateAcid salts | 25 |
| Lotus leaf extract | 4 |
| Green tea extract | 5 |
| Lotus seed powder (commercially available) | 8 |
| Limonin | 0.6 |
The preparation method comprises the following steps:
1) sieving each raw material with a 100-mesh sieve for later use;
2) weighing L-carnitine tartrate, lotus leaf extract, green tea extract and lotus seed powder according to the formula proportion, uniformly mixing, adding limonin with the formula amount, and mixing to obtain total mixed powder;
3) and filling the total mixed powder into capsules (260 mg/capsule based on L-carnitine tartrate) by using a capsule filling machine to obtain the L-carnitine tartrate capsules.
Example 2
Prescription:
| composition of matter | Dosage (kg) |
| L-carnitine tartrate | 27 |
| Lotus leaf extract | 3 |
| Green tea extract | 4 |
| Lotus seed powder (self-made) | 7 |
| Limonin | 0.3 |
The lotus seed powder self-making method comprises the following steps:
1) fresh lotus seeds with lotus plumule, and freeze drying;
2) primary crushing;
3) and (3) carrying out jet milling on compressed nitrogen at 4 ℃ to obtain the product.
The preparation method of the capsule comprises the following steps:
1) sieving each raw material with a 100-mesh sieve for later use;
2) weighing L-carnitine tartrate, lotus leaf extract, green tea extract and lotus seed powder according to the formula proportion, uniformly mixing, adding limonin with the formula amount, and mixing to obtain total mixed powder;
3) and filling the total mixed powder into capsules (260 mg/capsule based on L-carnitine tartrate) by using a capsule filling machine to obtain the L-carnitine tartrate capsules.
Example 3
Prescription:
the preparation method comprises the following steps: .
1) Sieving each raw material with a 100-mesh sieve for later use;
2) weighing L-carnitine tartrate, lotus leaf extract, green tea extract and lotus seed powder according to the formula proportion, uniformly mixing, adding limonin with the formula amount, and mixing to obtain total mixed powder;
3) and filling the total mixed powder into capsules (260 mg/capsule based on L-carnitine tartrate) by using a capsule filling machine to obtain the L-carnitine tartrate capsules.
Example 4
Prescription:
| composition of matter | Dosage (kg) |
| L-carnitine tartrate | 26 |
| Lotus leaf extract | 3.5 |
| Green tea extract | 4.5 |
| Lotus seed powder (self-made) | 7.6 |
| Limonin | 0.4 |
The lotus seed powder self-making method comprises the following steps:
1) fresh lotus seeds with lotus plumule, and freeze drying;
2) primary crushing;
3) and (3) carrying out jet milling on compressed nitrogen at 4 ℃ to obtain the product.
The preparation method of the capsule comprises the following steps:
1) sieving each raw material with a 100-mesh sieve for later use;
2) weighing L-carnitine tartrate, lotus leaf extract, green tea extract and lotus seed powder according to the formula proportion, uniformly mixing, adding limonin with the formula amount, and mixing to obtain total mixed powder;
3) and filling the total mixed powder into capsules (260 mg/capsule based on L-carnitine tartrate) by using a capsule filling machine to obtain the L-carnitine tartrate capsules.
The prescription composition of the comparative example is as follows:
the preparation method is the same as example 4.
The results of the effect test of the l-carnitine tartrate capsules prepared by the above embodiments of the present invention are as follows:
1) animal experiments of L-carnitine lotus leaf green tea capsules: the SPF male SD rats with the weight of 200-220 g are fed for 3 days adaptively, and are randomly divided into 11 groups according to the weight, a blank control group, a high-fat model control group, and examples 1-4 groups, control examples 1-3 groups, market 1 (Nippon Lepai L-carnitine lotus leaf green tea capsule) and market 2 (modified L-carnitine tea polyphenol tablet), the blank control group animals are fed with basic feed, and the model control group animals and other experimental groups are fed with high-fat feed. The food intake and water intake of each group of animals are controlled to be basically consistent, the animals of the blank control group and the animals of the model control group drink distilled water, and 3 animals of the experimental group drink dissolved capsule content or tablet water solution (30 mg/l/day calculated by L-carnitine tartrate) for 30 days. The weights of the animals in each group are counted, and the results show that the animals in the groups of examples 1-4 have good weight control effect, and the specific results are shown in table 1:
TABLE 1
2) The L-carnitine lotus leaf green tea capsule has the effect verification: female volunteers who were examined to have no organic lesions and only in an overweight state, aged 35-45 years and 900 in total, all volunteers were obese (body weight index BMI 28-32), were randomly divided into 9 groups, and were administered to examples 1-4, comparative examples 1-3, commercial 1 (Nippon L-carnitine L-lotus leaf green tea capsule) and commercial 2 (modified L-carnitine tea polyphenol tablet), respectively, each person took the L-carnitine product (780 mg/time, twice a day, calculated as L-carnitine tartrate) every day, continuously taken for 3 months, and compared to the average value of body weight index before and after 3 months of administration, and the incidence of adverse reactions is counted, and the results show that the L-carnitine tartrate capsule prepared in the embodiment has good weight-losing effect, and the incidence of adverse reactions such as insomnia, heartbeat acceleration, dizziness, palpitation, diarrhea and the like is obviously reduced, and the specific results are shown in the following table: 2:
TABLE 2
Claims (4)
1. The L-carnitine lotus leaf green tea capsule is characterized by being prepared from the following raw materials in parts by weight: 270 parts of L-carnitine tartrate 250-one, 30-40 parts of lotus leaf extract, 40-50 parts of green tea extract, 70-80 parts of lotus seed powder and 3-6 parts of limonin;
the lotus seed powder is prepared by the following steps:
a) removing impurities from semen Nelumbinis, and drying;
b) primary crushing;
c) micronizing;
the lotus seeds are fresh lotus seeds, and the drying mode is freeze drying.
2. The L-carnitine lotus leaf green tea capsule as claimed in claim 1, which is characterized by comprising the following raw materials in parts by weight: 260 parts of L-carnitine tartrate, 35 parts of lotus leaf extract, 45 parts of green tea extract, 76 parts of lotus seed powder and 4 parts of limonin.
3. The L-carnitine lotus leaf green tea capsule of claim 1, wherein the micronization in the lotus seed powder preparation step c) is air current pulverization, and the air current is composed of low-temperature compressed nitrogen.
4. The method for preparing L-carnitine lotus leaf green tea capsules as claimed in claim 1, comprising the following steps:
a) sieving the raw materials for later use;
b) weighing L-carnitine tartrate, lotus leaf extract, green tea extract and lotus seed powder according to the formula proportion, uniformly mixing, adding limonin with the formula amount, and mixing to obtain total mixed powder;
c) and filling the total mixed powder into capsules by using a capsule filling machine to obtain the capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910278268.4A CN109998102B (en) | 2019-04-09 | 2019-04-09 | L-carnitine lotus leaf green tea capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910278268.4A CN109998102B (en) | 2019-04-09 | 2019-04-09 | L-carnitine lotus leaf green tea capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109998102A CN109998102A (en) | 2019-07-12 |
| CN109998102B true CN109998102B (en) | 2022-04-29 |
Family
ID=67170353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910278268.4A Active CN109998102B (en) | 2019-04-09 | 2019-04-09 | L-carnitine lotus leaf green tea capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109998102B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125692A (en) * | 2010-01-13 | 2011-07-20 | 王华明 | Wrapping agent in levo-carnitine wrapping technology and composition of ten series products and preparation method |
| CN108294147A (en) * | 2018-03-30 | 2018-07-20 | 甘肃大整健康管理股份有限公司 | A kind of traditional Chinese medicine health care preparation for fat reducing hypoglycemic |
| CN108904716A (en) * | 2018-07-30 | 2018-11-30 | 吴威 | A kind of fat management composition, preparation method and application |
-
2019
- 2019-04-09 CN CN201910278268.4A patent/CN109998102B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125692A (en) * | 2010-01-13 | 2011-07-20 | 王华明 | Wrapping agent in levo-carnitine wrapping technology and composition of ten series products and preparation method |
| CN108294147A (en) * | 2018-03-30 | 2018-07-20 | 甘肃大整健康管理股份有限公司 | A kind of traditional Chinese medicine health care preparation for fat reducing hypoglycemic |
| CN108904716A (en) * | 2018-07-30 | 2018-11-30 | 吴威 | A kind of fat management composition, preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 纽倍乐牌左旋肉碱荷叶绿茶胶囊;国食健字G20150006;《药最网》;20160511;https://www.yaozui.com/baojianpin/4248-niubeilepaizuoxuanroujian hexieluchaxiaonang * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109998102A (en) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102907623B (en) | Pudding powder for losing weight and preparation method thereof | |
| CN102048884B (en) | Weight-losing composition containing guarana extract | |
| CN111280364A (en) | Composite oyster and polygonatum peptide solid beverage and production process thereof | |
| CN107691838A (en) | Pet sterilization sustained release cream and preparation method thereof | |
| CN104489681A (en) | Composition with function of enhancing immunity, health product and preparation method thereof | |
| CN102150838A (en) | Weight losing composition, preparation containing same and preparation method thereof | |
| CN110353046A (en) | A kind of milk protein solid beverage and its preparation process | |
| JP4397663B2 (en) | Muscle mass increasing agent | |
| CN109998102B (en) | L-carnitine lotus leaf green tea capsule and preparation method thereof | |
| CN107568375A (en) | A kind of adlay slim tea and preparation method thereof | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN104664168B (en) | A kind of piglet specific complex vitamin microemulsion preparation and its preparation method and application | |
| JP2022173374A (en) | oral composition | |
| CN102524325A (en) | Pregnant woman dedicated whole wheat flour and making method thereof | |
| CN102578179A (en) | Special flour for pregnant women and preparation method thereof | |
| CN107114795A (en) | A kind of weak base is replenished the calcium, soda alkalization ginger preparation and its preparation method and application | |
| JPH09238615A (en) | Health nutritive food | |
| JP7122727B2 (en) | Beverage containing ferulic acid | |
| CN109730303A (en) | A kind of endothelium corneum gigeriae galli crystallite medicinal granules of powder of food digesting stomach fortifying and preparation method thereof | |
| CN111493251A (en) | Solid beverage with synergistic weight-losing effect and preparation and eating methods thereof | |
| CN107233490A (en) | A kind of maca composition of supplementing qi and nourishing yin beautifying face and moistering lotion | |
| CN107173638A (en) | A kind of Chinese medicine fish meal including the peaceful root of purple-flowered peucedanum and preparation method thereof | |
| EP3960189A1 (en) | Antiviral composition having antiviral activity against coronavirus and variant viruses thereof | |
| CN108244643B (en) | Composition capable of controlling weight and improving athletic ability | |
| CN101342366A (en) | SOD oxidation resistant composition and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 236000 21 Xinhua Road, economic development zone, Yingdong District, Fuyang City, Anhui Province Patentee after: ANHUI QUANKANG PHARMACEUTICAL CO.,LTD. Address before: 236600 West District of Chengguan Town Industrial Park, Taihe County, Fuyang City, Anhui Province Patentee before: ANHUI QUANKANG PHARMACEUTICAL CO.,LTD. |
|
| CP02 | Change in the address of a patent holder |